Developing new treatments for schistosomiasis using nanobody technology
RNA encoded nanobody-based immunotherapeutics targeting essential, host-interactive schistosome ectoenzymes
This study is working on a new treatment for schistosomiasis, a disease caused by parasites, by creating tiny proteins that can help stop the parasites from making people sick, aiming to provide a better option for those affected.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10747442 on NIH RePORTER |
What this research studies
This research focuses on creating innovative immunotherapeutics to combat schistosomiasis, a disease caused by parasitic flatworms affecting millions worldwide. The approach involves generating nanobodies, which are small, effective binding agents, to target specific proteins on the surface of the schistosome parasites. By utilizing advances in RNA technology, these nanobodies can be delivered efficiently to inhibit the parasites' ability to infect their hosts. The goal is to develop a practical and potent treatment option for patients suffering from this debilitating disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in endemic regions who are infected with schistosomiasis or at high risk of infection.
Not a fit: Patients who do not have schistosomiasis or are not at risk of infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for schistosomiasis, improving health outcomes for millions of affected individuals.
How similar studies have performed: While the use of nanobodies in therapeutics is a novel approach, similar strategies targeting other parasitic infections have shown promise in preliminary studies.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Skelly, Patrick J — Tufts University Boston
- Study coordinator: Skelly, Patrick J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.